Travere Therapeutics
TVTX
169 hedge funds and large institutions have $1.27B invested in Travere Therapeutics in 2023 Q2 according to their latest regulatory filings, with 26 funds opening new positions, 83 increasing their positions, 41 reducing their positions, and 30 closing their positions.
102% more repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 41
3% less funds holding
Funds holding: 174 → 169 (-5)
5.07% less ownership
Funds ownership: 116.08% → 111% (-5.1%)
13% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 30
33% less capital invested
Capital invested by funds: $1.9B → $1.27B (-$627M)
40% less funds holding in top 10
Funds holding in top 10: 5 → 3 (-2)
81% less call options, than puts
Call options by funds: $1.9M | Put options by funds: $9.74M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$32.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$24.8M |
| 3 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$22.2M |
| 4 |
BlackRock
New York
|
+$19.4M |
| 5 |
Walleye Capital
New York
|
+$12.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
-$92.5M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$28.4M |
| 3 |
LCM
Laurion Capital Management
New York
|
-$22.2M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$17.2M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$15.9M |
TVTX Hedge Fund Activity: Q2 2023 in Review
169 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q2 2023, worth a combined $1.27B — down 33% from $1.9B a quarter earlier.
Sellers outnumbered buyers: 30 funds closed out of TVTX and 26 opened new positions — a net loss of 4 holders — while 41 trimmed existing stakes and 83 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $32.5M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $92.5M sold.
- 169 institutional investors held Travere Therapeutics (TVTX) as of Q2 2023, down from 174 in Q1 2023.
- Funds reported $1.27B of Travere Therapeutics stock for Q2 2023, down 33% quarter-over-quarter.
- 26 funds opened new Travere Therapeutics positions in Q2 2023 and 30 closed out, a net change of -4 holders.
- The largest Travere Therapeutics buyer in Q2 2023 was Point72 Asset Management, an estimated $32.5M added.
- The largest Travere Therapeutics seller in Q2 2023 was Adage Capital Partners, an estimated $92.5M sold.
Based on aggregated 13F filings for Q2 2023.